Actinium Pharmaceuticals Company Profile (NYSEMKT:ATNM)

About Actinium Pharmaceuticals (NYSEMKT:ATNM)

Actinium Pharmaceuticals logoActinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:ATNM
  • CUSIP: N/A
  • Web: www.actiniumpharma.com
Capitalization:
  • Market Cap: $78.69 million
  • Outstanding Shares: 55,807,000
Average Prices:
  • 50 Day Moving Avg: $1.45
  • 200 Day Moving Avg: $1.25
  • 52 Week Range: $0.86 - $2.19
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.52
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.32 per share
  • Price / Book: 4.41
Profitability:
  • EBIDTA: ($26,770,000.00)
Misc:
  • Average Volume: 583,377 shs.
  • Short Ratio: 2.6
 

Frequently Asked Questions for Actinium Pharmaceuticals (NYSEMKT:ATNM)

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "ATNM."

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) issued its quarterly earnings data on Monday, March, 16th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. View Actinium Pharmaceuticals' Earnings History.

Where is Actinium Pharmaceuticals' stock going? Where will Actinium Pharmaceuticals' stock price be in 2017?

3 brokerages have issued 1-year price targets for Actinium Pharmaceuticals' shares. Their forecasts range from $5.00 to $9.00. On average, they expect Actinium Pharmaceuticals' share price to reach $7.33 in the next year. View Analyst Ratings for Actinium Pharmaceuticals.

Who are some of Actinium Pharmaceuticals' key competitors?

Who owns Actinium Pharmaceuticals stock?

Actinium Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), Geode Capital Management LLC (0.00%) and Renaissance Technologies LLC (0.00%). Company insiders that own Actinium Pharmaceuticals stock include Kaushik J Dave, Richard I Steinhart, Sandesh Seth, Sergio Traversa and Sloan-Kettering Cance Memorial. View Institutional Ownership Trends for Actinium Pharmaceuticals.

Who sold Actinium Pharmaceuticals stock? Who is selling Actinium Pharmaceuticals stock?

Actinium Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Actinium Pharmaceuticals.

Who bought Actinium Pharmaceuticals stock? Who is buying Actinium Pharmaceuticals stock?

Actinium Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have bought Actinium Pharmaceuticals stock in the last two years include Kaushik J Dave, Richard I Steinhart, Sandesh Seth and Sergio Traversa. View Insider Buying and Selling for Actinium Pharmaceuticals.

How do I buy Actinium Pharmaceuticals stock?

Shares of Actinium Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Actinium Pharmaceuticals stock cost?

One share of Actinium Pharmaceuticals stock can currently be purchased for approximately $1.41.

Analyst Ratings

Consensus Ratings for Actinium Pharmaceuticals (NYSEMKT:ATNM) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.33

Analysts' Ratings History for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Show:
DateFirmActionRatingPrice TargetDetails
5/8/2017HC WainwrightReiterated RatingBuy$8.00View Rating Details
11/2/2016FBR & CoReiterated RatingBuy$9.00View Rating Details
10/21/2016Roth CapitalReiterated RatingBuy$5.00View Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Earnings by Quarter for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Earnings History by Quarter for Actinium Pharmaceuticals (NYSEMKT:ATNM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/2015Q4 2014($0.19)($0.17)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Current Year EPS Consensus Estimate: $-0.54 EPS
Next Year EPS Consensus Estimate: $-0.56 EPS

Dividends

Dividend History for Actinium Pharmaceuticals (NYSEMKT:ATNM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Insider Trades by Quarter for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Institutional Ownership by Quarter for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Insider Trades by Quarter for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/30/2016Sandesh SethInsiderBuy5,000$0.88$4,400.00View SEC Filing  
12/12/2016Sandesh SethInsiderBuy5,000$0.98$4,900.00View SEC Filing  
8/31/2016Sloan-Kettering Cance MemorialMajor ShareholderSell192,927$1.83$353,056.41View SEC Filing  
8/29/2016Sloan-Kettering Cance MemorialMajor ShareholderSell50,000$1.71$85,500.00View SEC Filing  
8/16/2016Sloan-Kettering Cance MemorialMajor ShareholderSell9,468$1.72$16,284.96View SEC Filing  
7/12/2016Sloan-Kettering Cance MemorialMajor ShareholderSell3,100$1.80$5,580.00View SEC Filing  
7/11/2016Sloan-Kettering Cance MemorialMajor ShareholderSell21,990$1.80$39,582.00View SEC Filing  
7/6/2016Sloan-Kettering Cance MemorialMajor ShareholderSell20,840$1.81$37,720.40View SEC Filing  
7/1/2016Sloan-Kettering Cance MemorialMajor ShareholderSell148,100$1.81$268,061.00View SEC Filing  
6/15/2016Sloan-Kettering Cance MemorialMajor ShareholderSell33,619$1.90$63,876.10View SEC Filing  
6/2/2016Sloan-Kettering Cance MemorialMajor ShareholderSell17,790$2.01$35,757.90View SEC Filing  
6/1/2016Sloan-Kettering Cance MemorialMajor ShareholderSell169,450$1.97$333,816.50View SEC Filing  
5/26/2016Sloan-Kettering Cance MemorialMajor ShareholderSell40,068$1.92$76,930.56View SEC Filing  
5/25/2016Sloan-Kettering Cance MemorialMajor ShareholderSell36,400$1.90$69,160.00View SEC Filing  
4/26/2016Sloan-Kettering Cance MemorialMajor ShareholderSell52,577$2.04$107,257.08View SEC Filing  
4/21/2016Sloan-Kettering Cance MemorialMajor ShareholderSell196,497$2.03$398,888.91View SEC Filing  
4/18/2016Sandesh SethChairmanBuy15,000$1.99$29,850.00View SEC Filing  
4/15/2016Sergio TraversaDirectorBuy3,000$2.02$6,060.00View SEC Filing  
4/14/2016Kaushik J DaveCEOBuy10,000$2.02$20,200.00View SEC Filing  
4/14/2016Richard I SteinhartDirectorBuy2,500$2.01$5,025.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Latest Headlines for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Source:
DateHeadline
streetinsider.com logoActinium Pharma (ATNM) Says EMA Granted Orphan Designation for Actimab-A
www.streetinsider.com - May 24 at 10:27 AM
streetinsider.com logoActinium Pharma (ATNM) Says EMA Granted Orphan Designation for Actimab-A - StreetInsider.com
www.streetinsider.com - May 24 at 9:51 AM
finance.yahoo.com logoActinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Actimab-A
finance.yahoo.com - May 24 at 9:51 AM
globenewswire.com logoActinium Pharmaceuticals to Present Actimab-A Data at the 10th International Symposium on Targeted Alpha Therapy - GlobeNewswire (press release)
globenewswire.com - May 23 at 9:29 AM
bizjournals.com logoResearch Reports Initiation on Biotech Stocks -- Agenus, Athersys, Actinium Pharma, and AVEO Pharma
www.bizjournals.com - May 19 at 9:22 AM
streetinsider.com logoActinium Pharma (ATNM) CEO and CTO Resign
www.streetinsider.com - May 16 at 8:49 PM
streetinsider.com logoActinium Pharma (ATNM) CEO and CTO Resign - StreetInsider.com - StreetInsider.com
www.streetinsider.com - May 16 at 8:49 PM
finance.yahoo.com logoAnthem Denies Cigna Breakup Fee as Merger Bid Crumbles
finance.yahoo.com - May 12 at 4:17 PM
streetinsider.com logoActinium Pharma (ATNM) Says It's Cleared by Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B - StreetInsider.com
www.streetinsider.com - May 11 at 4:07 PM
reuters.com logoBRIEF-Actinium Pharmaceuticals files for non-timely 10-Q
www.reuters.com - May 11 at 4:07 PM
nasdaq.com logoActinium Pharmaceuticals Receives Clearance from Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B - Nasdaq
www.nasdaq.com - May 10 at 9:05 AM
finance.yahoo.com logoActinium Pharmaceuticals Receives Clearance from Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B
finance.yahoo.com - May 10 at 9:04 AM
americanbankingnews.com logoActinium Pharmaceuticals Inc (ATNM) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - May 8 at 9:36 PM
americanbankingnews.com logoActinium Pharmaceuticals (ATNM) Given Media Impact Score of 0.22
www.americanbankingnews.com - April 29 at 10:52 AM
finance.yahoo.com logoActinium Pharmaceuticals Announces Sponsorship of the Acute Leukemia Forum 2017
finance.yahoo.com - April 18 at 10:11 AM
biz.yahoo.com logoACTINIUM PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial
biz.yahoo.com - March 28 at 8:40 PM
streetinsider.com logoActinium Pharma (ATNM) Appoints Ajit Shetty to the Board of Directors - StreetInsider.com
www.streetinsider.com - March 28 at 3:40 PM
streetinsider.com logoActinium Pharma (ATNM) Appoints Ajit Shetty to the Board of Directors
www.streetinsider.com - March 28 at 11:37 AM
finance.yahoo.com logoActinium Pharmaceuticals Appoints Pharmaceutical Industry Executive Ajit S. Shetty, Ph.D., to the Company’s Board of Directors
finance.yahoo.com - March 28 at 11:37 AM
bizjournals.com logoHow These Biotech Stocks are Faring? -- Actinium Pharma, Eleven Biotherapeutics, Neuralstem, and Aptose Biosciences
www.bizjournals.com - March 27 at 9:01 AM
investopedia.com logoMoleculin Leukemia Drug Gets Orphan Status (MBRX)
www.investopedia.com - March 22 at 4:13 PM
us.rd.yahoo.com logoActinium Announces Receipt of Positive Scientific Advice from the European Medicines Agency for Iomab-B
us.rd.yahoo.com - March 21 at 12:32 PM
streetinsider.com logoActinium Pharma (ATNM) Announces Notice of Allowance for U.S. Patent Related to Actimab-A, Actimab-M and Technology Platform
www.streetinsider.com - March 1 at 6:25 AM
finance.yahoo.com logoActinium Pharmaceuticals Announces Active Presence at the BMT Tandem Meetings
finance.yahoo.com - February 23 at 3:44 PM
finance.yahoo.com logoActinium Pharmaceuticals to Attend the BMT Tandem Meetings, the Combined Annual Meetings of Two Leading Transplant Organizations
finance.yahoo.com - February 14 at 4:24 PM
finance.yahoo.com logoActinium Pharmaceuticals’ Company Presentation at BIO CEO & Investor Conference to Provide Highlights of Recently Announced Actimab-M Trial in Multiple Myeloma
finance.yahoo.com - February 13 at 4:12 PM
finance.yahoo.com logoActinium Pharmaceuticals (ATNM) has Considerable Potential in 2017
finance.yahoo.com - February 10 at 4:11 PM
finance.yahoo.com logoActinium Pharmaceuticals to Present at BIO CEO & Investor Conference
finance.yahoo.com - February 9 at 3:50 PM
us.rd.yahoo.com logoActinium Pharmaceuticals Announces Pipeline Expansion with Initiation of Clinical Trial of Actimab-M in Multiple Myeloma
us.rd.yahoo.com - February 7 at 4:36 PM
us.rd.yahoo.com logo8:05 am Actinum Pharma initiates a Phase 1 clinical trial studying Actimab-M in multiple myeloma
us.rd.yahoo.com - February 7 at 4:36 PM
finance.yahoo.com logoActinium’s Chief Medical Officer, Dr. Mark Berger, to Present Talk Titled, Iomab-B: Radiolabeled CD45 at the 3rd Annual Expert Forum on Acute Leukemias and Myeloproliferative Neoplasms
finance.yahoo.com - January 24 at 4:07 PM
finance.yahoo.com logoActinium Announces Participation in Three Upcoming Hematology Events
finance.yahoo.com - January 20 at 4:43 PM
finance.yahoo.com logoActinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical Officer
finance.yahoo.com - January 18 at 4:19 PM
us.rd.yahoo.com logoActinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 Conference
us.rd.yahoo.com - January 4 at 3:49 PM
globenewswire.com logoActinium Pharmaceuticals to Present at LD Micro Main Event Investor Conference - GlobeNewswire (press release)
globenewswire.com - November 21 at 8:28 AM
finance.yahoo.com logoActinium Pharmaceuticals to Present at LD Micro Main Event Investor Conference
finance.yahoo.com - November 21 at 8:28 AM
finance.yahoo.com logoActinium Pharmaceuticals Announces Key Hire in Clinical Supply Chain Organization as Company Expands To Accommodate Continued Growth
finance.yahoo.com - October 31 at 9:39 AM

Social

This page was last updated on 5/25/2017 by MarketBeat.com Staff